-transparent.png){kind=logo}
A case of mococutaneous leishmaniasis in a patient referred to Memorial Sloan-Kettering Cancer Center, New York, with a presumptive diagnosis of lethal mid-line granuloma is described. The patient had lived in Bolivia and had been treated with antimony during and after which his mucosal lesions progressed. These lesions completely healed with 971 mg of amphotericin B. Mucocutaneous leishmaniasis is endemic in many areas of Central and South America and may occur in patients in the United States who have lived in or traveled to these areas. Organisms may be difficult to identify, and multiple biopsies and cultures may be necessary. The use of amphotericin B for the treatment of leishmaniasis is reviewed. It is an effective alternative to antimony therapy, and in some cases resistant to antimony, it may be the drug of choice.
C Singer, and
D Armstrong, and
T C Jones, and
R H Spiro
January 2008,
Revista da Sociedade Brasileira de Medicina Tropical,
C Singer, and
D Armstrong, and
T C Jones, and
R H Spiro
January 1964,
Revista de la Asociacion Medica Argentina,
C Singer, and
D Armstrong, and
T C Jones, and
R H Spiro
January 2007,
Journal of biomedicine & biotechnology,
C Singer, and
D Armstrong, and
T C Jones, and
R H Spiro
May 1976,
The Journal of tropical medicine and hygiene,
C Singer, and
D Armstrong, and
T C Jones, and
R H Spiro
August 1983,
East African medical journal,
C Singer, and
D Armstrong, and
T C Jones, and
R H Spiro
January 1971,
International journal of dermatology,
C Singer, and
D Armstrong, and
T C Jones, and
R H Spiro
August 2000,
The Journal of antimicrobial chemotherapy,
C Singer, and
D Armstrong, and
T C Jones, and
R H Spiro
July 1996,
Clinical and experimental dermatology,
C Singer, and
D Armstrong, and
T C Jones, and
R H Spiro
October 1960,
Archives of dermatology,
C Singer, and
D Armstrong, and
T C Jones, and
R H Spiro
June 2020,
The American journal of tropical medicine and hygiene,
